GMA
In the randomised double-blind placebo-controlled trial, 75 healthy adults aged 55–70 consumed maltodextrin or maltodextrin with 30 billion CFU/day of P. acidilactici PA53 for eight weeks. Faecal microbiota and serum biomarkers were assessed at baseline and completion.
Authors describe favourable changes in happiness, gastrointestinal-symptom and sleep scales in the PA53 group, together with lower IL-6 and TNF-alpha and shifts in the relative abundance of several microbial genera.
The result is strain-specific and cannot establish a probiotic category effect. Sample size, duration, multiple endpoints and questionnaire-based outcomes call for larger replication, clearly prespecified between-group testing and longer follow-up.
The study broadens the positioning of a probiotic strain beyond digestive health by connecting the gut–brain axis with ageing in a defined human population.
A small, short study with several self-reported endpoints in healthy adults. It does not show prevention of cognitive decline or transferability to other strains.
Editorial note. This content is intended for industry professionals. It does not constitute medical advice, therapeutic guidance or regulatory advice. Read our editorial method.
Read the original source · The Journal of Nutrition ↗